Michael Fishman, MD, MBA is a double board-certified Anesthesiologist and Interventional Pain Specialist at the Center for Interventional Pain and Spine (CIPS), where he also serves as Director of Research. He graduated from Jefferson Medical College in Philadelphia, PA and subsequently completed an internship in General Surgery at Lankenau Medical Center in Wynewood, PA. Thereafter, he earned a Master in Business Administration at Drexel University before returning to clinical medicine and completing residency in Anesthesiology at Yale-New Haven Hospital. During residency he developed a particular interest in Pain Medicine and neuromodulation, which he pursued fellowship training in at the Stanford Pain Management Center. Since then he has practiced comprehensive pain medicine utilizing neuromodulation, medications, medical cannabis, and a host of other therapies to restore function and improve quality of life in his patients. He believes in synergy between modalities, and thinks ‘outside the box’ when designing treatment plans for his patients. Dr. Fishman has designed and/or participated in over twenty-five clinical trials in the field of pain medicine and neurostimulation. Dr. Fishman has authored more than sixty peer-reviewed abstracts and publications in the scientific literature and has presented his work at numerous local, regional, and international society meetings. The wide-ranging nature of pain care and pain treatments is reflected in the diversity of research being performed in his clinic.

Dr. Michael Gofeld MD, PhD completed the fellowship training in Chronic Pain at the University of Toronto in 2005. He remained in academic medicine first on faculty at the University of Toronto and later, between 2009-2013, at the University of Washington. He returned to Ontario in 2013 and re-joined the Department of Anesthesia at the University of Toronto. After completing his PhD thesis and receiving an appointment as Associate Professor, Dr. Gofeld left the University in 2018 and became the Medical Director at Silver Pain Centre located in Toronto. The clinic provides interdisciplinary and interventional pain services. Dr. Gofeld is actively involved in the research and development of novel therapeutic methods and approaches in chronic pain management and allied health.

Michael Hartmann, MD FIPP MBA, is working 100% in pain medicine since 20 years. Several years he was head of Interventional Pain Therapy at Pain Clinic Basilea and head of Pain Medicine at Bethesda, Basilea. He then established Pain Clinic Zurich. In this interdisziplinary out-patient setting individual treatments are tailored utilizing interventional, rehabilitational and psychological approaches. His special interests are self-efficacy and minimally invasive pain treatments. He recently co-founded helpyourcells to offer regenerative interventional (pain) treatment. After education at Hamburg University, he was engaged in cardiac and neuro anesthesia and intensive care medicine at Hannover Medical University and Freiburg University. He published on Alpha-2-agonists, ventilator-associated pneumonia and analgosedation during interventional pain procedures. He held the first patent on a silver-coated endotracheal tube. He is lecturer for the Swiss Society for the Studies of Pain (SGSS) and examiner for the World Institute of Pain (WIP).

Craig T. Hartrick, MD, is a former Professor of Biomedical Sciences (Pharmacology), a Professor of Anesthesiology (retired) at Oakland University William Beaumont School of Medicine and Clinical Professor of Health Sciences (Pharmacology) at Oakland University in Rochester, Michigan. He completed 12 years of service as Editor-in-Chief of Pain Practice and is a past President of the World Institute of Pain. His research interests have included both basic and clinical science, with over 70 studies as principal investigator. He is well published, with over 200 peer-reviewed articles, abstracts, and textbook chapters. As President, Co-founder and CSO of Caventure Drug Discovery, Inc., his current investigations are devoted to novel analgesic discovery.